David Christian Harmon MD (He/Him)
[Pronunciation: Harmon ]
Hematology/Oncology
Assistant Professor, Medicine-Massachusetts General Hospital, Harvard Medical School
Join to View Full Profile
55 Fruit St Yaw 7Mass General HospitalBoston, MA 02114
Phone+1 617-462-9473
Fax+1 617-726-2894
Dr. Harmon is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. David Harmon is an oncologist based in Boston, MA, who graduated from Harvard Medical School in 1974. His research has been published in journals such as Oncotarget and Scientific Reports, focusing on topics like osteosarcoma and potential oncogenic markers. His work has involved significant studies on targeting programmed cell death ligand 1 using CRISPR/Cas9 and analyzing androgen receptors in osteosarcoma. Dr. Harmon has been involved in clinical trials investigating the effects of combining Thalidomide with radiation and chemotherapy for treating primary soft tissue sarcoma.
Education & Training
Harvard Medical SchoolClass of 1979
Rhode Island Hospital/Brown University HealthResidency, Internal Medicine, 1977 - 1979- Rhode Island Hospital/Brown University HealthInternship, Internal Medicine, 1976 - 1977
The Warren Alpert Medical School of Brown UniversityMMSc., Biology Medical Sciences , 1974 - 1976
Brown UniversityB.Sc., Biology , Magna cum laude, 1970 - 1974
Certifications & Licensure
MA State Medical License 1974 - 2017
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
Clinical Trials
- Preoperative Thalidomide With Radiation Therapy For Patients With Low-Grade Primary Soft Tissue Sarcoma or Thalidomide With Radiation Therapy and Chemotherapy For Patients With High-Grade or Intermediate-Grade Primary Soft Tissue Sarcoma of the Arm, Leg, or Body Wall Start of enrollment: 2004 Jun 17
Publications & Presentations
PubMed
- Correction: Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells.Yunfei Liao, Lulu Chen, Yong Feng, Jacson Shen, Yan Gao
Oncotarget. 2024-02-05 - Author Correction: Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11.Yunfei Liao, Slim Sassi, Stefan Halvorsen, Yong Feng, Jacson Shen
Scientific Reports. 2024-01-22 - 1 citationsAuthor Correction: Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11.Yunfei Liao, Slim Sassi, Stefan Halvorsen, Yong Feng, Jacson Shen
Scientific Reports. 2018-08-09
Research History
- Assistant Professor of MedicineChemotherapy of soft tissue and bone sarcomas and molecular biology and targeting of their cells1980 - 2017
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
